TheRightDoctors Logo
Pre Alpha
Insights from the world's best medical minds
nine
Insights from the world's best medical minds

Learning The Do's And Don’t's With The SCAI Fellows Course

The SCAI Fellows Course Was All About The Possibilities And How To Put The Patient First

Dr. Ramesh Daggubati

Dr. Ramesh Daggubati, Clinical Professor, East Carolina Heart Institute
Pause
Love It
Download

Share this video

45 Total views

Dr. Ramesh Daggubati

Clinical Professor

East Carolina Heart Institute


"The fellows course was run over two days, and was very well attended" Dr. Ramesh Daggubati commented on the SCAI Fellows Course that took place at CSI-NIC 2015. The course focused on improving quality, increasing integrity amongst physicians and also took a look at recent interventional cardiology trials.


More than 50% Indian patients live in ar...: Dr.Santanu Guha


To share keytakeaways from your medical practice write to us at editorial@therightdoctors.com. Stay Updated with Insights from The World's Best Medical Minds, by connecting with us on Facebook and Twitter.


Share this video | 20 Shares

45 Total views

Complete Transcript

Dr.Ramesh Daggubati

I actually was one of the colleagues with Dr. Matheen Khuddus and we ran the meeting for fellows which is called The Society of Coronary Angiography and Intervention Meeting. This is an organization from United States of America. The fellow’s course was run over two days. It was very well attended by nearly 100 to 150 cardiology fellows from the different parts of India and we have given several talks over here and we discussed about how to improve quality and trying to create integrity among the physicians to discuss their complex cases and we also shared about several lectures including the recent interventional cardiology trials. The most important point in this recent interventional clinical trial is duration of antiplatelet therapy needs to be individualized based on their risk score for bleeding as well as stent thrombosis. So there is no standard dual antiplatelet therapy anymore. People can be given 6 months worth of, even 12 months or sometimes longer upto 30 months. The other point in interventional trials is actually partner trial which is intermediate risk trial that has been recently presented at American College of Cardiology that showed that intermediate risk patients with severe aortic stenosis do better with the transfemoral transcatheter aortic valve replacement compared to open aortic valve replacement. So this is a new thing that is much more powerful, TAVI is here to stay and many people will be addressed by this percutaneous method of treating aortic stenosis rather than open aortic valve replacement, but at the end we have to focus on hot team approach involving the general cardiologist, cardiac surgeon and interventional cardiologist and sometimes even anesthesiologist as a team and decide what is the best for the patient and obviously the patient has to be the one who has to make a decision after receiving an informed consent from explaining the risks, benefits and alternatives of different therapies. So this is the main source of presentation and this is our take home point from NIC which is an excellent and fantastic meeting that happened over two-and-a-half days in Hyderabad.



the interview

in conversation

the speakers

one more thing